E

EuBiologics Co Ltd
KOSDAQ:206650

Watchlist Manager
EuBiologics Co Ltd
KOSDAQ:206650
Watchlist
Price: 11 940 KRW 0.59%
Market Cap: 436.2B KRW
Have any thoughts about
EuBiologics Co Ltd?
Write Note

EuBiologics Co Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

EuBiologics Co Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
E
EuBiologics Co Ltd
KOSDAQ:206650
Cash & Cash Equivalents
â‚©9.9B
CAGR 3-Years
22%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Cash & Cash Equivalents
â‚©564.6B
CAGR 3-Years
-15%
CAGR 5-Years
1%
CAGR 10-Years
15%
SK Bioscience Co Ltd
KRX:302440
Cash & Cash Equivalents
â‚©127B
CAGR 3-Years
72%
CAGR 5-Years
95%
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Cash & Cash Equivalents
â‚©182.9B
CAGR 3-Years
61%
CAGR 5-Years
4%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Cash & Cash Equivalents
â‚©114.6B
CAGR 3-Years
53%
CAGR 5-Years
39%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Cash & Cash Equivalents
â‚©27B
CAGR 3-Years
15%
CAGR 5-Years
22%
CAGR 10-Years
N/A
No Stocks Found

EuBiologics Co Ltd
Glance View

Market Cap
435.3B KRW
Industry
Biotechnology

EuBiologics Co., Ltd. engages in the research, development, and manufacture of biopharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 323 full-time employees. The company went IPO on 2017-01-24. The firm operates its business through two segments. The Vaccine segment manufactures and sells oral cholera vaccines. The Contract Research and Manufacturing Organization (CRMO) segment contracts, researches and manufactures biopharmaceuticals.

Intrinsic Value
17 631.48 KRW
Undervaluation 32%
Intrinsic Value
Price
E

See Also

What is EuBiologics Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
9.9B KRW

Based on the financial report for Sep 30, 2024, EuBiologics Co Ltd's Cash & Cash Equivalents amounts to 9.9B KRW.

What is EuBiologics Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
7%

Over the last year, the Cash & Cash Equivalents growth was 24%. The average annual Cash & Cash Equivalents growth rates for EuBiologics Co Ltd have been 22% over the past three years , 7% over the past five years .

Back to Top